| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 26 Jun 2025 | 26 Jun 2025 |
| Disclosure under Regulation 30 of the SEBI Listing Regulations | ||
| Board Meeting | 28 May 2025 | 26 Mar 2025 |
| Suven Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2025 inter alia to consider and approve the financial results for the period ended March 31 2025 Financial Results for period ended March 31, 2025 (As Per BSE Announcement Dated on :28.05.2025) | ||
| Board Meeting | 25 Apr 2025 | 25 Apr 2025 |
| Intimation of Effective Date of merger and Record Date | ||
| Board Meeting | 12 Feb 2025 | 27 Dec 2024 |
| Suven Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2025 inter alia to consider and approve Unaudited Financial Results for the quarter and nine months ending December 31 2024 Outcome of the Board Meeting (As Per BSE Announcement Dated on 12/02/2025) | ||
| Board Meeting | 12 Nov 2024 | 26 Sep 2024 |
| Suven Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2024 inter alia to consider and approve the Un-audited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ending September 30 2024 Outcome of the Board Meeting (As per BSE Announcement Dated on 12/11/2024) | ||
| Board Meeting | 19 Sep 2024 | 19 Sep 2024 |
| Change in Directorate | ||
| Board Meeting | 9 Aug 2024 | 2 Aug 2024 |
| Suven Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/08/2024 inter alia to consider and approve With reference to above subject pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 please note that a Meeting of the Board of Directors of the Company will be held on Friday the 09th August 2024 at 01:00 p.m. IST at the Corporate Office 202 A-Wing Galaxy Towers Plot No.1 Hyderabad Knowledge City TSIIC Raidurg Hyderabad Telangana - 500081 of the Company to consider inter alia and approve the following matter(s): To consider and approve the Un-audited Financial Results (Standalone and Consolidated) of the Company under Ind AS for the first quarter ended June 30 2024 and other matters. Please further note that TRADING WINDOW for dealing in the securities of the company is already closed from 01st July 2024 as per PIT Code of the Company. Trading window will be opened from 12th August 2024. Outcome of the Board Meeting Appointment of Company Secretary and Compliance Officer effective from September 03, 2024 (As per BSE Announcement Dated on 09/08/2024) | ||
Revenue from operations of the company stood at ₹307.2 crore, with a Year-on-Year (YoY) growth of 39.8% quarter over Q3 FY24 as compared to ₹219.8 crore
Suven is now a prominent player in the ADC outsourcing market, estimated to be worth $2.7 billion (approx. ₹22,815 Crore).
Here are some of the stocks that may see significant price movement today: Adani Enterprises, Siemens, Aurobindo Pharma, etc.
Here are some of the stocks that may see significant price movement today: HCL Technologies, Lupin, Piramal Pharma, etc.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
